National Health Determination under paragraph 98C(1)(b) Amendment 2019 (No.6) (PB 59 of 2019) (Cth)

PB 59 of 2019

National Health Determination under paragraph 98C(1)(b) Amendment 2019 (No. 6)

National Health Act 1953

___________________________________________________________________________

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under paragraph 98C(1)(b) of the National Health Act 1953.

Dated   26 July 2019

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

___________________________________________________________________________

1. Name of Instrument

(1)This Instrument is the National Health Determination under paragraph 98C(1)(b) Amendment 2019 (No.6).

(2)This Instrument may also be cited as PB 59 of 2019.

1. Commencement

This Instrument commences on 1 August 2019.

1. Amendments to Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)

Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).

Schedule 1     Amendments

1. Schedule 4, after entry for Fluticasone in the form Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms per dose, 60 doses

insert:

Fluticasone furoate	Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose, 30 doses
Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms per dose, 30 doses

1. Schedule 4, entry for Hypromellose

omit:

Eye drops 3 mg per mL, 15 mL

1. Schedule 4, after entry for Testosterone in the form Transdermal gel (pump pack) 12.5 mg per 1.25 g dose, 60 doses, 2

insert:

Transdermal gel (pump pack) 23 mg per 1.15 g dose, 56 doses